The FINANCIAL — The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in the United States. The three-month dosing ...
Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...
TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...
The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...
Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...
The judge rejected Mylan's claim that the 693 patent was invalid based on obviousness, meaning that a person of ordinary skill in the art could have formulated the patent's claims using publicly ...
Teva, Viatris revive patent challenge on J&J's long-acting schizophrenia blockbuster Invega Sustenna
After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of Invega Hafyera, a twice-yearly injectable antipsychotic for adults with schizophrenia. The approval of this 6-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback